{"entity":{"id":"hair-topical-prevention-agents","kind":"technology","name":"Creams and lotions tried to prevent chemotherapy hair loss","aka":[],"tldr":"Several drugs have been put on the scalp to stop chemotherapy hair loss before it starts: minoxidil lotion, vitamin D analogues, and others. The trials were done and they did not work. Scalp cooling remains the only method cleared by a regulator to prevent it.","summary":"This record exists so that the question is answered rather than left open, because it is the first thing people ask and the answer is unwelcome. A meta-analysis of interventions to prevent chemotherapy-induced alopecia (Shin et al., International Journal of Cancer 2015) pooled 8 randomised and 9 controlled trials covering 1,098 participants. Scalp cooling significantly reduced the risk of alopecia, with a relative risk of 0.38 (95 per cent confidence interval 0.32 to 0.45); topical 2 per cent minoxidil and the other interventions tested did not significantly reduce it.\n\nThe individual failures are worth naming. Topical minoxidil was tested for prevention in a randomised trial of 48 women receiving doxorubicin (Rodriguez et al., Annals of Oncology 1994): 88 per cent and 92 per cent of patients in the two arms had severe alopecia, a difference that was not significant. Topical calcipotriol, a vitamin D analogue that protects rodent hair follicles, was tested in a randomised controlled trial in women receiving CMF chemotherapy (Bleiker et al., British Journal of Dermatology 2005) and had no detectable effect on any measure: the proportion with minimal hair loss, shed rates, plucked telogen and fractured hair counts, the shape of shed and plucked hair, regrowth or hair density. An earlier phase 1 study of topical calcitriol found that all 14 patients developed moderate alopecia and that eight developed a toxic rash where the drug had been applied.\n\nNewer topical calcitriol formulations reached phase 1 in taxane-treated patients and were reported as safe, with alopecia of less than 50 per cent in 8 of 23 patients at week 7, but no phase 2 or phase 3 trial of it has been registered. AS101, a tellurium compound, prevented alopecia as an incidental finding in a 44-patient trial designed to test marrow protection, and no trial of it for hair has been registered since. The practical conclusion for a reader is that minoxidil is a treatment for hair that is slow to return, not a shield for hair you still have, and that the only prevention with a regulator behind it is cooling.","status":"negative","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Chemotherapy-induced_alopecia","links":[{"label":"Shin et al., efficacy of interventions for prevention of chemotherapy-induced alopecia: systematic review and meta-analysis (International Journal of Cancer 2015)","url":"https://doi.org/10.1002/ijc.29115"},{"label":"Bleiker et al., atrophic telogen effluvium from cytotoxic drugs and a randomised controlled trial of topical calcipotriol (British Journal of Dermatology 2005)","url":"https://doi.org/10.1111/j.1365-2133.2005.06608.x"},{"label":"Lacouture et al., prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines (Annals of Oncology 2021)","url":"https://doi.org/10.1016/j.annonc.2020.11.005"}],"tags":["complementary","supportive-care","hair-loss","evidence:no-benefit"],"related":[],"cancers":[],"sections":["rejuvenation","supportive-care","chemotherapy"],"technologies":["scalp-cooling","minoxidil-chemotherapy-alopecia","cytotoxic-chemotherapy"],"targets":[],"drugs":["doxorubicin","docetaxel","paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":["hair-anagen-effluvium"],"trials":[],"people":[],"bottlenecks":["b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Each of these aimed to make the follicle temporarily less vulnerable, by pushing it out of the dividing phase or by local cell-cycle arrest, so that a drug circulating in the blood would do it less damage. Scalp cooling takes the other route, reducing how much of the drug arrives.","strengths":["The question has actually been tested, repeatedly, rather than left to opinion","Knowing what does not work stops money and hope going to it"],"limitations":["Individual trials were small","Negative results for one dose and schedule do not rule out another","Newer agents stalled after phase 1 rather than failing outright, which is a different kind of nothing"]},"route":"/technologies/hair-topical-prevention-agents/","neighbours":{"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"term":[{"id":"hair-anagen-effluvium","kind":"term","name":"Anagen effluvium (chemotherapy hair loss)","route":"/terms/hair-anagen-effluvium/"}],"bottleneck":[{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}]}}